Navigation Links
Nuvilex Completes First Sale of Last Shot Hangover Remedy(TM)
Date:7/15/2009

CHERRY HILL, N.J., July 15 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), announced today that it completed its first sale of its Last Shot Hangover Remedy. The sale, a 36 shot case of Last Shot Hangover Remedy(TM), was made to a local bar establishment by the first of Nuvilex' fifteen new commission sales representatives. The sale marks Nuvilex' official launch of its Last Shot Hangover Remedy(TM) across the U.S., concentrating in major markets in the following order: Philadelphia, New York City, Miami, Chicago, Las Vegas, San Francisco, Los Angeles, San Diego, Boston, Washington, DC, Atlanta, New Orleans, Dallas, Phoenix, and Seattle. The initial target customers are the approximate 70,000 bar establishments in the US. The Company, through third party distributor agreements, will expand to restaurants, clubs, resort hotels and international markets later this year. Direct to consumer Internet sales will commence in August 2009.

Last Shot Hangover Remedy(TM) is a calorie-free, liquid, nutritional supplement that contains a concentrated blend of vitamins, essential amino acids, and other beneficial ingredients. Last Shot Hangover Remedy(TM) helps the body to combat symptoms that are associated with alcohol-induced hangovers, including nausea, fatigue, and headache. Last Shot Hangover Remedy(TM) retails for $4.00 per three quarter ounce shot. Approximately 35 hangover remedy products are currently sold worldwide, generally through pharmacies. Nuvilex' "at the bar" distribution strategy is a market differentiator and provides a competitive advantage that ideally fits with the unanticipated consequences of excessive alcohol consumption. The total potential market size in the US for hangover remedy products is estimated to be $10-50 million per year. The Company forecasts $1 to $3 million in Last Shot Hangover Remedy(TM) sales for FY 2010 and substantial growth in subsequent years.

In March 2009, Nuvilex conducted a proof of concept study among 6,000 college-aged students who drank to the point of intoxication. Nuvilex determined the efficacy of Last Shot by asking study participants to indicate what symptoms they experienced during excessive alcohol consumption with and without Last Shot. The feedback the Company received on the efficacy of Last Shot was overwhelmingly positive; students who drank to excess (defined as > 6 drinks/night) and did not receive Last Shot were nearly 6 times more likely to experience a hangover or symptoms that are associated with a hangover.

Nuvilex has conceived, formulated, tested, test marketed, commenced pilot scale manufacturing and launched its Last Shot Hangover Remedy(TM) in less than six months. The Company, in pilot scale, is capable of producing 1,000 cases per month. Full-scale production, via an FDA certified packing company; with full market production capabilities will be online by September 2009. At full-scale production levels, the Company believes it can achieve a greater than 75% gross margin.

Nuvilex, as part of its comprehensive marketing plan for its Last Shot Hangover Remedy, is producing a thirty and sixty-second Last Shot Hangover Remedy video commercial, which will be ready to air through various media outlets by August 1, 2009. The video commercial is being directed by Miller + Partners, Coral Springs, FL.

"Nuvilex is a small company and we are very proud of our ability to get the Last Shot Hangover Remedy(TM) out of the lab and into the market in record time," said Martin Schmieg, Chairman and Chief Executive Officer of Nuvilex, Inc. "The Last Shot Hangover Remedy(TM) is a fun and highly effective product. Our 'at the bar' marketing strategy is intended to make the Last Shot Hangover Remedy 'a part of the party'. Everyone enjoys a good party. Our Last Shot Hangover Remedy is designed for a better morning after. We are extremely excited to have introduced the Last Shot Hangover Remedy into the large and fragmented hangover remedy market, and we are confident in the revenues and stabilizing profits Last Shot will bring to the Company."

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy, a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen, which promotes a healthy glucose metabolism; Cinnechol, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink( (R)), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink( (R)). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Amy Glynn/Ashleigh Barreto
    The Ruth Group
    Ph: 646-536-7023/7028
    Email: aglynn@theruthgroup.com
    Email: abarreto@theruthgroup.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Announces Business Update Conference Call
2. Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol, Can Help to Improve Cardiovascular Health
3. Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream
4. Nuvilex Featured in Wall Street Reporter Interview
5. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
6. Nuvilex Launches Video Marketing Campaign
7. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
8. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
9. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
10. Nuvilex, Inc. Announces Monthly Investor Conference Call
11. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... containerization, today announced an exhibitor sponsorship at MobileIron Live! 2017 in ... new technologies for an immersive, educational approach to helping organizations maximize the benefits ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, ... today announced it has completed a round of funding to accelerate its growth ... partners. Black Granite Capital is a growth equity firm focused on investments in ...
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... , ... RawTrition now brings you BioEnergy which is a powder capsule whole ... , RawTrition is taking nutrients to the next level! The superfoods in RawTrition's ... form (unlike the synthetically made options that are on the market). , Founder of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a leader ... in a new class of photodynamic cosmetics (PDC). , Allumera® is the first ... outward signs of aging, and minimize the appearance of pores – all with ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology: